OverviewSuggest Edit

Nouscom develops a technology platform that is based on tumor targeted oncolytic viruses and patient-specific cancer vaccines. The Company offers Endovax antigenless vaccine that encodes immunomodulators, breaks tolerance, and primes/rescues cancer-specific immune response; and Exovax personalized vaccine that encodes neoantigens and boosts cancer-specific responses for sustained immunity. Its technology is based on viral vectors and oncolytic viruses.

TypePrivate
Founded2015
HQBasel, CH
Websitenouscom.com
Employee Ratings1

Latest Updates

Employees (est.) (Jun 2019)23(+5%)

Key People/Management at Nouscom

Alfredo Nicosia

Alfredo Nicosia

Chief Executive Officer and Co-Founder
Elisa Scarselli

Elisa Scarselli

Chief Scientific Officer and Co-Founder
Stefano Colloca

Stefano Colloca

Chief Technical Officer and Co-Founder
Antonella Folgori

Antonella Folgori

Senior Director of Immunology and Co-Founder
Cinzia Traboni

Cinzia Traboni

Senior Director of Regulatory Affairs and Co-Founder
Marina Udier

Marina Udier

COO
Show more

Nouscom Office Locations

Nouscom has offices in Basel and Roma
Basel, CH (HQ)
18 Bäumleingasse
Roma, IT
100 Via di Castel Romano
Show all (2)

Nouscom Financials and Metrics

Summary Metrics

Founding Date

2015

Nouscom total Funding

$62.6 m

Nouscom latest funding size

$49 m

Time since last funding

2 years ago

Nouscom investors

Nouscom's latest funding round in November 2017 was reported to be $49 m. In total, Nouscom has raised $62.6 m
View all funding rounds

Nouscom News and Updates

Nouscom - IND for NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors

BASEL, Switzerland, June 3, 2019 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that its Investigational New Drug (IND) application for the first clinical trial of its lead candidate NOUS-209 has...

Nouscom Strengthens Board of Directors with the Appointment of John F. McDonald as an Independent Director

BASEL, Switzerland, November 5, 2018 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its proprietary technology platform, announced today that it has appointed John F. McDonald as an...

Nouscom Blogs

IND for NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors

BASEL, Switzerland – 3rd June 2019: Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that its Investigational New Drug (IND) application for the first clinical trial of its lead candidate NOUS-209 has been cleared by the US Foo…

Dr. Marina Udier, COO of Nouscom, will give a talk about our company at the BaselArea.swiss Life Science Event on June 20, 2019 in Basel

The BaselArea.swiss Life Science event will have Dr. Marina Udier, COO of Nouscom, talking about the story of the company and sharing insights and learnings along the way. L'articolo Dr. Marina Udier, COO of Nouscom, will give a talk about our company at the BaselArea.swiss Life Science Event on Jun…

Nouscom will present at the NeoAg Summit 2018

The 3rd NeoAg Summit is the leading end-to-end industry- focused meeting dedicated to advancing neoantigen-based cancer vaccines and cell therapies. Download the full program of NeoAg Summit 2018. L'articolo Nouscom will present at the NeoAg Summit 2018 proviene da Nouscom.

Nouscom will present at the World Vaccine Congress Europe 2018

Find out the full program here: https://www.terrapinn.com/conference/world-vaccine-congress-europe/agenda.stm   L'articolo Nouscom will present at the World Vaccine Congress Europe 2018 proviene da Nouscom.

Nouscom Appoints Adrian Woolfson, M.D., Ph.D as Chief Medical Officer

BASEL, Switzerland – 29th May 2018 Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its clinically validated Exovax platform, announced today the appointment of Adrian Woolfson M.D., Ph.D. as Chief Medical Officer (CMO). …

Nouscom Frequently Asked Questions

  • When was Nouscom founded?

    Nouscom was founded in 2015.

  • Who are Nouscom key executives?

    Nouscom's key executives are Alfredo Nicosia, Elisa Scarselli and Stefano Colloca.

  • How many employees does Nouscom have?

    Nouscom has 23 employees.

  • Who are Nouscom competitors?

    Competitors of Nouscom include Repair Biotechnologies, Stealth BioTherapeutics and CAMP4 Therapeutics.

  • Where is Nouscom headquarters?

    Nouscom headquarters is located at 18 Bäumleingasse, Basel.

  • Where are Nouscom offices?

    Nouscom has offices in Basel and Roma.

  • How many offices does Nouscom have?

    Nouscom has 2 offices.